NDAORALTABLETPriority Review
Approved
Jul 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Mechanism of Action
RNA Replicase Inhibitors
Pharmacologic Class:
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Clinical Trials (2)
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
Started May 2016
77 enrolled
Chronic Hepatitis C
Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
Started Nov 2015
554 enrolled
Hepatitis C
Loss of Exclusivity
LOE Date
Dec 1, 2037
142 months away
Patent Expiry
Dec 1, 2037